Leica Biosystems receives FDA clearances for AI-assisted quality control and digital pathology scanners
Leica Biosystems has received FDA clearance for its AI-assisted quality control solution and its digital pathology scanners. The news was reported on 11 August.
Who is affected and how
- doctor
- Pathologists gain a wider range of FDA-cleared digital workflow tools.
- hospital manager
- A new cleared option is available when planning digital pathology investments.
- medtech company
- Cleared AI quality control sets a competitive benchmark in the pathology scanner market.
Sources
- Leica Biosystems Receives FDA Clearances for AI-Assisted Quality Control and Digital Pathology Scannersclinical lab products · Aug 11, 2026
- Leica Biosystems enables faster cancer diagnoses through multiple digital pathology FDA clearances, including industry-first AI-assisted quality control softwarenews-medical · Aug 11, 2026
- Leica Biosystems Gains FDA Clearance for AI Pathology QC Software and Scannersclpmag.com · Aug 11, 2026
- New FDA-Cleared Scanners and Quality Control Software Aim to Scale Digital Pathology | ASCO AI in Oncologyascoai.org · Aug 12, 2026
Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.